跳至主要内容
临床试验/DRKS00005009
DRKS00005009已完成不适用

A non-interventional observational study in adults and children from 5 years of age assessing the safety and tolerability of GRAZAX® in case of concomitant specific immunotherapy (SCIT or SLIT)

ALK-Abelló Arzneimittel GmbH0 个研究点目标入组 181 人开始时间: 2013年5月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
181

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
5 Years 至 one(—)
性别
All

入选标准

  • The tolerability of the grass immunotherapy tablet (GRAZAX) during routine treatment is recorded in children and adults who are treated concomitantly with additional specific immunotherapy for treatment of further allergies.

排除标准

  • Contraindications of specific immunotherapy

研究者

相似试验